STOCK TITAN
  1. Home
  2. News
  3. CRIS

Curis Inc - CRIS STOCK NEWS

Welcome to our dedicated news page for Curis (Ticker: CRIS), a resource for investors and traders seeking the latest updates and insights on Curis.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Curis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Curis's position in the market.

News
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Curis, Inc. announced the approval of an inducement stock option grant to a new employee, consisting of 8,550 shares of common stock, with a grant date of April 1, 2024. The option has a 10-year term, vests over four years, and was granted outside of the company's stock incentive plan. This move aims to attract and retain talent crucial for the company's growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.93%
Tags
none
-
News
Curis to Present at Upcoming Healthcare Conferences in April
Rhea-AI Summary
Curis, Inc. announces participation in the 23rd Annual Needham Virtual Healthcare Conference. James Dentzer, President and CEO, will present on April 8, 2024, focusing on innovative cancer therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.48%
Tags
conferences
-
News
Curis Provides Fourth Quarter 2023 Business Update
Rhea-AI Summary
Curis, Inc. reported positive clinical data at ASH, showing 3 out of 5 patients achieved CR in R/R PCNSL. Expansion of clinical sites in the US and Europe is underway, with cash runway into 2025. The company also announced a partnership to study the combination of emavusertib and pembrolizumab in patients with metastatic melanoma. Financially, the company reported a net loss of $47.4 million for the year ended December 31, 2023, with revenues of $10.0 million and cash, cash equivalents, and investments totaling $56.3 million as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.42%
Tags
earnings
News
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024
Rhea-AI Summary
Curis, Inc. (CRIS) will release its fourth quarter 2023 financial results on February 8, 2024, and will host a conference call at 8:30 a.m. ET. The company is focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
earnings
-
News
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Curis, Inc. (NASDAQ: CRIS) announced the approval of a grant of inducement stock options to a new employee, totaling 5,800 shares of Curis common stock, with a grant date of January 2, 2024. The stock option has a 10-year term and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the employee's date of hire and an additional 6.25% vesting on each successive three-month period thereafter, subject to the employee's continued service with the Company. The stock option was granted as an inducement equity award outside of the Company's Fourth Amended and Restated 2010 Stock Incentive Plan and was made as an inducement material to the employee's acceptance of employment with the Company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.87%
Tags
none
-
News
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study
Rhea-AI Summary
Curis, Inc. (NASDAQ: CRIS) announces positive initial combination study data for emavusertib (CA-4948) in the TakeAim Lymphoma trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.61%
Tags
none
News
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference
Rhea-AI Summary
Curis, Inc. (CRIS) presents positive clinical data from its TakeAim Leukemia Study at the 2023 ASH Conference, demonstrating the safety and anti-cancer activity of emavusertib in patients with FLT3 mutation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.93%
Tags
clinical trial
-
News
Curis Announces Three Presentations at ASH
Rhea-AI Summary
Curis, Inc. (NASDAQ: CRIS) will present three posters at the 65th ASH Annual Meeting and Exposition, showcasing the continued progress of emavusertib (CA-4948) in clinical studies in leukemia and lymphoma. The presentations will highlight the preliminary safety and efficacy of emavusertib in acute myeloid leukemia patients with FLT3 mutation, as well as the ongoing trials evaluating the safety, PK/PD, and clinical activity of emavusertib in combination with Ibrutinib in patients with relapsed or refractory hematologic malignancies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.5%
Tags
none
-
News
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma
Rhea-AI Summary
Curis, Inc. (NASDAQ: CRIS) has entered into an investigator-initiated clinical trial agreement with the University of Florida to study the combination of emavusertib and pembrolizumab in patients with metastatic melanoma. The company is responsible for supplying emavusertib, while Merck will supply pembrolizumab and cover clinical study costs. Both companies retain 100% of the commercial rights to their respective programs. The Phase 1/2 study (NCT05669352) is expected to begin enrollment in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
none
News
Curis Provides Third Quarter 2023 Business Update
Rhea-AI Summary
Curis, Inc. reported its business update and financial results for Q3 2023. Patient enrollment has restarted in Phase 1/2 studies for emavusertib, with updated data expected in Q1 2024. The company plans to initiate a triplet combination study for AML in Q4 2023. Curis expects to present updated data from the TakeAim Lymphoma combination study at ASH in December. The company also highlighted a strong balance sheet with $68.5 million in cash and investments, providing a cash runway into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.25%
Tags
earnings
Stock CRIS logo
Curis Inc

Nasdaq:CRIS

CRIS Rankings

#5148 Ranked by Market Cap
#13 Ranked by Stock Gains
N/A Ranked by Dividends

CRIS Stock Data

90.06M
4.88M
0.19%
34.87%
0.85%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Lexington

About CRIS

curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl